Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: anti-tau immunotherapy in scientific journal 'Brain'

UCB and University of Lille antitau immunotherapy research highlighted in prestigious international scientific journal ‘Brain’Research demonstrates potential for antitau immunotherapy in treatment of Alzheimers and other taudriven diseases including progressive supranuclear palsy PSPFindings, combined with previous in vitro research, highlight important differences between tau... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: AGM 2019

UCBs General Meeting of ShareholdersFor financial year 2018:Gross dividend of € 1.21 per share 2.5%, payable 30 April 2019All agenda items put to vote approvedBrussels Belgium, 25 April 2019 – 18:00 CEST – regulated information Today, UCB held its Annual General Meeting of Shareholders AGM. At the AGM, 143 259 561 shares 76.07% of shares entitled to vote were represented. During the... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Cimzia at SPIN

New Data Showcases the Value of CIMZIA® certolizumab pegol in Patients with Psoriasis96week safety data from Phase 3 CIMPASI1, CIMPASI2 and CIMPACT studies confirm positive longterm safety profile of CIMZIA® certolizumab pegol in moderatetosevere plaque psoriasisFirst presentation of nail disease data from Phase 3 psoriasis studies demonstrate that 66.2% of patients achieved total resolution of... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Transparency Notification

Transparency notification BlackRock, Inc.Notification referring to situation on 3 April 2019Threshold crossed: 5%Latest holding: 5.49 %Brussels Belgium, 10 April 2019 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Evenity FDA, April 2019

FDA Approves Evenity™Romosozumab For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For FractureBelgium BRUSSELS April 9, 2019 – UCB Euronext Brussels: UCB and Amgen NASDAQ: AMGN today announced that the U.S. Food and Drug Administration FDA has approved EVENITY™ romosozumab for the treatment of osteoporosis in postmenopausal women at high risk for fracture. In the U.S.,... See more